Cidara Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Cidara Therapeutics

14/08/2024 24:36

* Cidara Therapeutics Inc  CDTX.OQ  reported a quarterly
adjusted
loss of $19.99​​ per share for the quarter ended in June, lower
than the same quarter last year, when the company reported EPS
of $-2.80.  The mean expectation of two analysts for the quarter
was for a loss of $3.22 per share. Wall Street expected
results to range from $-4.10 to $-2.35 per share.
    * Revenue fell 96% to $302.00 thousand from a year ago;
analysts
expected $4.70 million. 
    * Cidara Therapeutics Inc shares had fallen by 1.8% this
quarter and lost 26.2% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 153.9% in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Cidara
Therapeutics Inc is $40.00 
This summary was machine generated from LSEG data August 13 at
11:36 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -3.22          -19.99         Missed
 Mar. 31 2024      -0.20          -2.28          Missed
 Dec. 31 2023      -3.25          -0.80          Beat
 Sep. 30 2023      -3.25          -1.80          Beat